Skip to main content
Caplight Logo









Excalipoint Therapeutics

Excalipoint Therapeutics

Private
ShanghaiHealthcare & Life Scienceshttps://excalipoint.com/

Last Round

Seed

Mar 18, 2026

Total Funding Raised

$109.7M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Excalipoint Therapeutics is a biotechnology company developing next-generation T-cell engager (TCE) therapies for cancer and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

T-cell engagerTCEbispecific antibodytri-specific antibodyimmunotherapycancer therapeuticsautoimmune disease treatmentprobodyantibody engineeringbiotech startupclinical-stage biotechdrug developmentbiopharmaoncology pipelineout-licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Excalipoint Therapeutics Comparables

Compare Excalipoint Therapeutics with similar companies based on industry and business-model similarity.

Excalipoint Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Kali Therapeutics
84%
Suzhou Zelgen Biopharmaceuticals Co Ltd
73%
Merck
73%

Excalipoint Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMar 18, 2026
SeedAug 1, 2025

Excalipoint Therapeutics Investors

Notable investors and investment history

Excalipoint Therapeutics investors
InvestorRounds
Centurium CapitalSeed
Co-Win VenturesSeed
YuanBio Venture CapitalSeed
Eisai InnovationSeed
Hony CapitalSeed
5Y CapitalSeed
MPCSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 18, 2026

    $69M round led by Centurium Capital and HongShan.

Excalipoint Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Excalipoint Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Excalipoint Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Year Founded2025
Last FundingMar 18, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?